Premium
Deferasirox removes cardiac iron and attenuates oxidative stress in the iron‐overloaded gerbil
Author(s) -
AlRousan Rabaa M.,
Paturi Satyanarayana,
Laurino Joseph P.,
Kakarla Sunil K.,
Gutta Anil K.,
Walker Ernest M.,
Blough Eric R.
Publication year - 2009
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21487
Subject(s) - deferasirox , oxidative stress , medicine , gerbil , ferritin , endocrinology , thalassemia , ischemia
Iron‐induced cardiovascular disease is the leading cause of death in iron‐overloaded patients. Deferasirox is a novel, once daily oral iron chelator that was recently approved for the treatment of transfusional iron overload. Here, we investigate whether deferasirox is capable of removing cardiac iron and improving iron‐induced pathogenesis of the heart using the iron overload gerbil model. Animals were randomly divided into three groups: control, iron overload, and iron overload + deferasirox treatment. Iron‐dextran was given 100 mg/kg per 5 days i.p for 10 weeks. Deferasirox treatment was taken post iron loading and was given at 100 mg/kg/day p.o for 1 or 3 months. Cardiac iron concentration was determined by inductively coupled plasma atomic emission spectroscopy. Compared with the untreated group, deferasirox treatment for 1 and 3 months decreased cardiac iron concentration 17.1% ( P = 0.159) and 23.5% ( P < 0.05), respectively. These treatment‐associated reductions in cardiac iron were paralleled by decreases in tissue ferritin expression of 20% and 38% at 1 and 3 months, respectively ( P < 0.05). Using oxyblot analysis and hydroethidine fluorescence, we showed that deferasirox significantly reduces cardiac protein oxidation and superoxide abundance by 36 and 47.1%, respectively ( P < 0.05). Iron‐induced increase in oxidative stress was also associated with increased phosphorylation of ERK‐, p38‐, and JNK‐mitogen‐activated protein kinase (MAPK). Interestingly, deferasirox treatment significantly diminished the phosphorylation of all three MAPK subfamilies. These results suggest that deferasirox may confer a cardioprotective effect against iron induced injury. Am. J. Hematol. 2009. © 2009 Wiley‐Liss, Inc.